This is a working overview of TH9507, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-30 and is reviewed periodically as new material appears.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Heart tissue, like all cells in the body, needs to be supplied with oxygen, nutrients and a way of removing metabolic wastes. This is achieved by the coronary circulation, which includes arteries, veins, and lymphatic vessels. Blood flow through the coronary vessels occurs in peaks and troughs relating to the heart muscle's relaxation or contraction. Heart tissue receives blood from two arteries which arise just above the aortic valve. These are the left main coronary artery and the right coronary artery. The left main coronary artery splits shortly after leaving the aorta into two vessels, the left anterior descending and the left circumflex artery. The left anterior descending artery supplies heart tissue and the front, outer side, and septum of the left ventricle. It does this by branching into smaller arteries—diagonal and septal branches. The left circumflex supplies the back and underneath of the left ventricle. The right coronary artery supplies the right atrium, right ventricle, and lower posterior sections of the left ventricle. The right coronary artery also supplies blood to the atrioventricular node (in about 90% of people) and the sinoatrial node (in about 60% of people). The right coronary artery runs in a groove at the back of the heart and the left anterior descending artery runs in a groove at the front. There is significant variation between people in the anatomy of the arteries that supply the heart. The arteries divide at their furthest reaches into smaller branches that join at the edges of each arterial distribution.
=== Range === The conversion efficiency is essentially 100% from minimum detectable levels up to a flow of CO or CO2 at the detector of about 5×10−5g/s. These represent a detection limit of about 200 ppb and a maximum concentration of about 10% in a 0.5mL sample. Both values are dependent upon peak width.
From a scientific standpoint, it was a well characterized protein, whose structure had already been elucidated, making it easier to work with, in theory. Additionally, the widely available insulin at the time was pig insulin, and many people presented allergic reactions to this insulin. Human insulin, then, was preferable, for it was believed that people would not have allergic reactions to it. From a business standpoint, there was a large market for insulin; at the time, world sales were greater than $100 million, and growing. Boyer agreed that the insulin hormone should be their first target molecule. After concluding the market research, Swanson prepared Genentech's first business proposal by March 1976. It was with this proposal that Swanson pitched Genentech to Kleiner & Perkins. Perkins later explained that they considered the technical risks to be enormous: "(The risk of failure was) Very high. I figured better than 50–50 we'd lose it... (However) If it worked, the rewards would be obvious.". Boyer's scientific expertise and Swanson's business plan convinced the venture capitalists. While acknowledging the tremendous risk associated with the company, Kleiner and Perkins promised to invest $100,000 in Genentech. This was just a small fraction of Kleiner and Perkins's $8 million venture capital fund.
=== Excess facial hair in women === The topical cream is indicated for treatment of facial hirsutism in women. It is the only topical prescription treatment that slows the growth of facial hair. In clinical studies with Vaniqa, 81% of women showed clinical improvement after twelve months of treatment. Positive results were seen after eight weeks. However, discontinuation of the cream caused regrowth of hair back to baseline levels within 8 weeks. Vaniqa treatment significantly reduces the psychological burden of facial hirsutism.
Sources: en.wikipedia.org
Historically a major population center, Detroit has undergone a considerable reduction in population, losing over 60% of its population since 1950. Detroit reached its population peak in the 1950 census at 1.85 million people, and its population has decreased in each subsequent census. As of the 2020 census, the city has about 640,000 residents, a total loss of 65% of its 1950 population. The vast majority of this population loss was due to Detroit's deindustrialization, which moved factories from the inner city to the suburbs. This was coupled with the phenomenon of white flight, the movement of many white families from urban areas of metro Detroit to the suburbs on the city's outskirts. White flight was spurred on by the Great Migration, in which hundreds of thousands of black people migrated from the South to Detroit in search of employment. This caused overcrowding in the inner city and led to racial housing segregation. Practices of redlining, mortgage discrimination, and racially restrictive covenants in Detroit further contributed to the overcrowding of certain minority groups residing in subsections of Detroit, such as Black Bottom. Many of the white residents of Detroit did not wish to integrate with their black counterparts. They often chose to flee the city and reside in racially homogenous suburban neighbourhoods. This was also a result of an increased desire for homeownership. A report, "The Population Revolution in Detroit", published in February 1963 by Wayne State University sociologist Albert J.
== External links == GeneReviews/NCBI/NIH/UW entry on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy, Autosomal Dominant OMIM entries on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy, Autosomal Dominant Overview of all the structural information available in the PDB for UniProt: P10600 (Transforming growth factor beta-3) at the PDBe-KB.
=== Chemistry of saturated vs unsaturated acids === The reactivity of saturated fatty acids is usually associated with the carboxylic acid or the adjacent methylene group. By conversion to their acid chlorides, they can be converted to the symmetrical fatty ketone laurone (O=C(CnH(2n+1))2). Treatment with sulfur trioxide gives the α-sulfonic acids. The reactivity of unsaturated fatty acids is often dominated by the site of unsaturation. These reactions are the basis of ozonolysis, hydrogenation, and the iodine number. Ozonolysis (degradation by ozone) is practiced in the production of azelaic acid ((CH2)7(CO2H)2) from oleic acid.
== Recognition == 2022 – IDLO was included in the Forbes Next 250 list. The company reported UAH 32 million in sales. 2023 – IDLO received the ISPO Award, an international prize in the outdoor and sports gear industry. 2024 – The compan received the “Tested in Antarctica” mark from the National Antarctic Scientific Center of Ukraine. This distinction recognizes national manufacturers whose products have successfully endured Antarctic conditions. IDLO was the first company to receive this mark, acknowledging its long-term collaboration with the Academician Vernadsky station.
==== Education ==== Family, friends, and co-workers of a person with diabetes may provide life-saving treatment in the case of a hypoglycemic episode. It is important for these people to receive training on how to recognize hypoglycemia, what foods to help the hypoglycemic eat, how to administer injectable or intra-nasal glucagon, and how to use a glucose meter.
Sources: en.wikipedia.org
== History and production == Its industrial production was developed in Italy by Antonio Carpenè in collaboration with Enrico Comboni. Originally it was separated directly from the red wine (in which it is present for approximately 1% of the total) by precipitating it with basic lead acetate and obtaining a dark blue substance. Today, enocyanin is obtained from the peels of black grapes rich in anthocyanins (Italian cultivars "Ancellotta", "Colorino", "Sangiovese", "Lambrusco") by extraction in acidified water (often with citric or tartaric acid) at medium temperature (30–50°C) so as not to degrade the anthocyanins, sometimes with the addition of food-grade ethanol to improve yield and conservation. After separating the solids (seeds, fibers, and spent peels) using pressure filters or centrifugation, the extract is purified using ion exchange resins or membrane filtration, concentrated under low-temperature vacuum to preserve thermolabile compounds, and, if necessary, transformed into a powder through freeze-drying or spray-drying. The final product is stabilized with natural antioxidants and packaged in dark, airtight containers, often under an inert atmosphere. Classified as E163, enocyanin is used in the winemaking industry as a color enhancer and in the food and cosmetic industries for its intense pigmentation, excellent color stability in acidic environments, and its natural origin based on the recovery of winemaking byproducts. The starting pomace must be fresh and free of sulfur dioxide or other additives that could interfere with the extraction process.
=== Starvation === Starvation is a rare cause of ketoacidosis, usually instead causing physiologic ketosis without ketoacidosis. Ketoacidosis from starvation most commonly occurs in the setting of an additional metabolic stressor such as pregnancy, lactation, or acute illness.
Because this reaction is metal-free and proceeds with fast kinetics (k2 as fast as 60 1/Ms, faster than both the CuAAC or the SPAAC) SPANC can be used for live cell labeling. Moreover, substitution on both the carbon and nitrogen atoms of the nitrone dipole, and acyclic and endocyclic nitrones are all tolerated. This large allowance provides a lot of flexibility for nitrone handle or probe incorporation. However, the isoxazoline product is not as stable as the triazole product of the CuAAC and the SpAAC, and can undergo rearrangements at biological conditions. Regardless, this reaction is still very useful as it has notably fast reaction kinetics. The applications of this reaction include labeling proteins containing serine as the first residue: the serine is oxidized to aldehyde with NaIO4 and then converted to nitrone with p-methoxybenzenethiol, N-methylhydroxylamine and p-ansidine, and finally is incubated with cyclooctyne to give a click product. The SPANC also allows for multiplex labeling.
Similarly, the farmer populations worked the system of collective farms to grow food to feed the industrial workers in the industrialised cities. Since the mid-1930s, Marxism–Leninism has advocated an austere social-equality based upon asceticism, egalitarianism, and self-sacrifice. In the 1920s, the Bolshevik party semi-officially allowed some limited, small-scale wage inequality to boost labour productivity in the economy of the Soviet Union. These reforms were promoted to encourage materialism and acquisitiveness in order to stimulate economic growth. This pro-consumerist policy has been advanced on the lines of industrial pragmatism as it advances economic progress through bolstering industrialisation. In the economic praxis of Bolshevik Russia, there was a defining difference of political economy between socialism and communism. Lenin explained their conceptual similarity to Marx's descriptions of the lower-stage and the upper-stage of economic development, namely that immediately after a proletarian revolution in the socialist lower-stage society the practical economy must be based upon the individual labour contributed by men and women, and paid labour would be the basis of the communist upper-stage society that has realised the social precept of the slogan "From each according to his ability, to each according to his needs."
== Synthesis and Structure == All seven relaxin family peptide hormones are synthesized as pre-prohormones, and subsequently cleaved to form two chains stabilized by an intra-α-chain and two disulfide bonds. Members of the human relaxin peptide family share a similar tertiary structure, composed of a β-chain, c-chain, and α-chain at their carboxyl-terminal. All members of the relaxin family peptide hormones bind to their cognate receptors via residues present in their α- and β-chains.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.